Brief: Intercept Announces New Data Showing Potential Of Fixed-Dose Combination Of OCA And Bezafibrate

Intercept Pharmaceuticals

07/06/2023 12:25

June 7 (Reuters) - Intercept Pharmaceuticals Inc
 ICPT.O :
    * INTERCEPT ANNOUNCES NEW DATA SHOWING POTENTIAL OF
FIXED-DOSE
COMBINATION OF OCA AND BEZAFIBRATE TO NORMALIZE MULTIPLE
BIOMARKERS IN PBC TO BE FEATURED IN PODIUM PRESENTATION AT EASL
CONGRESS 2023
    * INTERCEPT PHARMACEUTICALS INC - OCA 5-10 MG + BEZAFIBRATE
400 MG
ALSO SHOWED RAPID BIOCHEMICAL RESPONSE OF MEAN ALP TO WITHIN
NORMAL RANGE AT 4 WEEKS
    * INTERCEPT PHARMACEUTICALS INC - COMBINATION WAS WELL
TOLERATED
WITH LOW RATES OF PRURITUS

Source text for Eikon:  ID:nGNXbdK9Ts 
Further company coverage:  ICPT.O